title: The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors.
abstract: Although adjuvant imatinib (IM) for high risk GIST is an accepted treatment consideration, the duration of therapy remains controversial. The recently published SSGXVIII/AIO randomized clinical trial of 3 years vs. 1 year of adjuvant IM has established a benefit of RFS and OS for the 3 year cohort. Future studies are necessary to continue to further delineate risk variables for GIST recurrence.
authors: Department of Surgery, Section of Surgical Oncology, Geisel School of Medicine at Dartmouth Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA. burton.l.eisenberg@dartmouth.edu
authors: Burton L
authors: BL
authors: Eisenberg
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D017326:Clinical Trials, Phase III as Topic; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D011743:Pyrimidines / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate